Middle East and Africa Hepatitis B Infection Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Middle East and Africa Hepatitis B Infection Market Size

• The Middle East and Africa hepatitis B infection market size was valued at USD 1.55 billion in 2024 and is expected to reach USD 2.31 billion by 2032, at a CAGR of 5.20% during the forecast period
• The market growth is largely fueled by the growing adoption of advanced diagnostic technologies and therapeutic innovations for Hepatitis B, coupled with increasing digitalization and integration of electronic health systems across Europe
• Furthermore, rising consumer and public health demand for accurate, accessible, and preventive solutions is establishing Hepatitis B management protocols as a central focus of healthcare policy. These converging factors are accelerating the adoption of vaccination, screening, and antiviral therapies, thereby significantly boosting the Hepatitis B Infection market growth across the region

Middle East and Africa Hepatitis B Infection Market Analysis

• Hepatitis B treatments and diagnostics are increasingly vital components of the Middle East and Africa’s public health systems, especially across both hospital and community-based care settings, due to growing infection awareness, improved access to testing, and advancements in antiviral therapies
• The escalating demand for effective Hepatitis B management is primarily fueled by government-led vaccination programs, rising HBV-HDV co-infection screening, and the increasing burden of chronic liver diseases, particularly among aging and high-risk populations
• Saudi Arabia dominated the Middle East and Africa hepatitis B infection market with the largest revenue share of 34.7% in 2024, characterized by comprehensive national immunization programs, early adoption of advanced diagnostic tools, and wide-scale HBV screening initiatives. The country has experienced a steady increase in treatment uptake, particularly among at-risk populations, supported by strong awareness campaigns and accessible public healthcare services
• U.A.E. is expected to be the fastest growing region in the Middle East and Africa Hepatitis B Infection market, driven by widespread implementation of hepatitis screening in employment and visa processes, high vaccination coverage, and access to modern healthcare facilities. Continuous R&D efforts and the country’s thriving medical tourism sector also support innovation and growth in HBV management
• The chronic hepatitis B segment dominated the Middle East and Africa hepatitis B infection market with a market share of 62.4% in 2024, attributed to the persistent and long-term nature of the disease, requiring ongoing antiviral therapy and surveillance, along with enhanced detection rates due to expanded public health screening programs

Report Scope and Middle East and Africa Hepatitis B Infection Market Segmentation

Middle East and Africa Hepatitis B Infection Market Trends

“Enhanced Convenience Through Integrated Care and Advanced Treatment Access”

• A significant and accelerating trend in the Middle East and Africa hepatitis B infection market is the growing integration of multidisciplinary care models and advanced treatment access through centralized healthcare systems. This trend is significantly improving patient outcomes and adherence by enabling seamless communication between general practitioners, hepatologists, and public health institutions
  • For instance, several Western European countries have implemented national hepatitis action plans that allow patients to receive early diagnosis, antiviral treatment, and regular follow-up care under one coordinated framework. Germany’s integrated care model, for instance, enables efficient linkage from diagnosis to treatment, reducing disease progression rates
• Efforts such as centralized patient registries, digital health record systems, and streamlined referral pathways are optimizing hepatitis B infection management by enabling timely intervention and monitoring. These systems allow healthcare providers to track liver function, treatment response, and co-infections such as hepatitis D in real-time
• The integration of advanced diagnostics with routine primary care services facilitates early detection of both acute and chronic cases. This centralized approach, combined with affordable access to newer antiviral therapies, enhances both individual patient care and broader public health surveillance
• This trend toward more streamlined, coordinated, and technology-supported hepatitis B care is fundamentally reshaping expectations within national healthcare systems. As a result, many European governments are expanding access to viral hepatitis screening, particularly among vulnerable and high-risk populations such as migrants, intravenous drug users, and the elderly
• The demand for accessible, efficient, and integrated hepatitis B treatment models is rapidly growing across both public and private healthcare sectors, as stakeholders increasingly focus on long-term disease control and alignment with the World Health Organization’s 2030 hepatitis elimination goals

Middle East and Africa Hepatitis B Infection Market Dynamics

Driver

“Growing Need Due to Rising Disease Burden and Preventive Healthcare Adoption”

• The increasing prevalence of hepatitis B infections across Europe, along with heightened awareness about liver diseases, is significantly driving the demand for early diagnosis, vaccination, and treatment solutions
  • For instance, in April 2024, GlaxoSmithKline plc (GSK) expanded its European hepatitis B vaccine supply through a strategic partnership with regional healthcare systems, aiming to improve immunization rates across high-risk populations. Such initiatives by key market players are expected to fuel growth in the Middle East and Africa Hepatitis B Infection market over the forecast period
• As public health authorities and consumers become more aware of the long-term complications associated with chronic hepatitis B—such as cirrhosis and liver cancer—the adoption of preventive strategies such as vaccination and early screening continues to rise
• Furthermore, the integration of hepatitis B testing into routine health check-ups and the growing popularity of point-of-care diagnostic technologies are making hepatitis B management more accessible and efficient across Europe
• The availability of effective vaccines, oral antiviral drugs, and the development of advanced immune modulators are enabling better disease control. Government funding, reimbursement policies, and WHO-led hepatitis elimination goals are also boosting adoption rates in both public and private healthcare settings

Restraint/Challenge

“Concerns Regarding Treatment Accessibility and High Cost of Advanced Therapies”

• Despite medical advancements, limited access to advanced antiviral therapies and immune modulators in certain parts of Middle East and Africa remains a challenge, particularly in Eastern and Southern Middle East and Africa where healthcare disparities persist
  • For instance, studies published in early 2024 indicated that some EU member states still face shortages in hepatitis B vaccines and limited access to novel treatment regimens due to procurement and reimbursement issues
• Bridging this gap requires policy-level efforts to harmonize hepatitis B care standards across all European nations, particularly through EU-level funding support, price negotiations, and streamlined regulatory approvals
• Moreover, while first-line antiviral drugs are becoming more affordable, newer generation therapies with improved efficacy often come at a higher cost, potentially limiting their uptake among uninsured or low-income populations
• Public mistrust or vaccine hesitancy, especially in post-pandemic Europe, is another barrier that must be addressed through awareness campaigns and healthcare provider engagement
• Overcoming these challenges through expanded insurance coverage, public-private partnerships, and increased investment in regional healthcare infrastructure will be crucial to sustaining long-term growth in the Middle East and Africa Hepatitis B Infection market

Middle East and Africa Hepatitis B Infection Market Scope

The market is segmented on the basis of type, and treatment.

• By Type

On the basis of type, the Middle East and Africa hepatitis B infection market is segmented into chronic and acute. The chronic segment dominated the largest market revenue share of 62.4% in 2024, primarily due to the high prevalence of chronic HBV cases and the need for lifelong disease management through antiviral therapies and monitoring.

The acute segment is anticipated to witness the fastest growth rate with a CAGR of 6.4% from 2025 to 2032, fueled by enhanced early screening efforts, public health initiatives, and growing awareness leading to timely diagnosis and treatment.

• By Treatment

On the basis of treatment, the Middle East and Africa hepatitis B infection market is segmented into vaccine, antiviral drugs, immune modulator drugs, and surgery. The vaccine segment held the largest revenue share of 41.2% in 2024, supported by national vaccination drives, increased birth-dose immunization, and strong uptake among high-risk adult populations.

The antiviral drugs segment is projected to witness the fastest CAGR of 7.1% from 2025 to 2032, driven by the expanding chronic HBV patient pool, advancements in oral therapies, and favorable reimbursement policies.

Middle East and Africa Hepatitis B Infection Market Regional Analysis

• Middle East and Africa dominated the hepatitis B infection market with the largest revenue share of 33.27% in 2024, driven by strong public health infrastructure, high vaccination coverage, and increasing awareness about hepatitis B transmission and prevention
• The region is characterized by advanced diagnostic capabilities, well-established immunization programs, and active government-led hepatitis surveillance initiatives
• This widespread adoption of preventive and therapeutic measures is further supported by universal healthcare access, continuous R&D investments, and the growing focus on early screening and disease control, positioning Middle East and Africa as a key contributor to the global Hepatitis B Infection market

Saudi Arabia Hepatitis B Infection Market Insight

The Saudi Arabia hepatitis B infection market accounted for 34.7% of the Middle East and Africa Hepatitis B infection market revenue in 2024. The market benefits from strong public health infrastructure, mandatory vaccination for infants and healthcare workers, and comprehensive awareness programs. The government’s focus on early detection and treatment, along with digitized health tracking, supports robust market performance.

U.A.E. Hepatitis B Infection Market Insight

The U.A.E. hepatitis B infection market contributed 16.7% of the regional revenue share in 2024. Widespread implementation of hepatitis screening in employment and visa processes, high vaccination coverage, and access to modern healthcare facilities are driving market growth. Continuous R&D efforts and medical tourism also support innovation in HBV management.

South Africa Hepatitis B Infection Market Insight

The South Africa hepatitis B infection market held a 15.2% market share in 2024. Government-backed hepatitis B vaccination programs, integration of HBV care into HIV treatment platforms, and growing community-level education campaigns are accelerating diagnosis and treatment rates, especially in under-resourced regions.

Egypt Hepatitis B Infection Market Insight

The Egypt hepatitis B infection market represented 13.8% of the regional hepatitis B infection market in 2024. The country’s focus on infectious disease control, universal infant immunization, and public-private healthcare partnerships are key drivers. Increased screening in antenatal and rural health programs is boosting early detection.

Middle East and Africa Hepatitis B Infection Market Share

The Middle East and Africa Hepatitis B Infection industry is primarily led by well-established companies, including:

• Gilead Sciences, Inc. (U.S.)
• GSK plc (U.K.)
• Dynavax Technologies (U.S.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Bristol-Myers Squibb Company (U.S.)
• Merck & Co., Inc. (U.S.)
• Novartis AG (Switzerland)
• Arrowhead Pharmaceuticals Inc. (U.S.)
• Arbutus Biopharma (Canada)
• Teva Pharmaceuticals, Inc. (Israel)
• Zydus Pharmaceuticals (India)
• Aurobindo Pharma (India)
• Lupin Pharmaceuticals, Inc. (India)

Latest Developments in Middle East and Africa Hepatitis B Infection Market

• In September 2024, Gilead Sciences and Genesis Therapeutics announced a strategic collaboration to discover and develop novel small molecule therapies using Genesis’ GEMS AI platform. Gilead gained exclusive rights to develop and commercialize products from this partnership
• In July 2024, Gilead Sciences, Inc. presented research data, showcasing long-term efficacy and safety of Biktarvy in diverse HIV populations, including Hispanic/Latine individuals and older adults with comorbidities. Investigational once-daily and weekly dosing regimens were also highlighted
• In February 2024, GSK completed its acquisition of Aiolos Bio, including the promising AIO-001 monoclonal antibody for severe asthma. GSK paid USD 1000 million upfront and up to USD 400 million in milestone payments, expanding its respiratory biologics portfolio

SKU-72953